AIM To make efficacy and safety comparison of telbivudineraodmap and tenofovir-roadmap in hepatitis B e antigen(HBe Ag)-negative chronic hepatitis B(CHB) patien
The first generation direct antiviral agents (DAAs)highlighted substantial prognosis improvement amongliver transplant (LT) candidates and recipients withrecurrent